01725nas a2200505   4500000000100000000000100001000000100002008004100003653001100044653005700055653005900112653001100171653000900182653002200191653001600213653001400229653000900243653001000252653004000262653001400302653002200316653003000338653003000368653001700398653001600415653008400431653008000515653007900595653008600674653007100760100001400831700001600845700001300861700001200874700001400886700001600900700001300916700001100929700001400940700001600954245021300970250001501183490000701198020001401205       2024                            d10aHumans10a*Diabetes Mellitus, Type 2/epidemiology/drug therapy10a*Electronic Health Records/statistics & numerical data10aFemale10aMale10a*Machine Learning10aMiddle Aged10aPrognosis10aAged10aAdult10aHypoglycemic Agents/therapeutic use10aIncidence10aFollow-Up Studies10adiabetes mellitus, type 210aElectronic Health Records10aepidemiology10aInformatics10abiopharmaceutical company, and declare stock and stock options. AB has received10aresearch funding from AstraZeneca. KK has acted as a consultant, speaker or10areceived grants for investigator-initiated studies for AstraZeneca, Bayer,10aNovartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer10aIngelheim, Oramed Pharmaceuticals, Roche and Applied Therapeutics.1 aM. Mizani1 aA. Dashtban1 aL. Pasea1 aQ. Zeng1 aK. Khunti1 aJ. Valabhji1 aJ. Mamza1 aH. Gao1 aT. Morris1 aA. Banerjee00aIdentifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals  a2024/06/050 v12  a2052-4897